James F.  Young net worth and biography

James Young Biography and Net Worth

Director of Novavax
Dr. Young joined the Novavax board of directors in April 2010 and was appointed chairman in April 2011. He has more than 30 years of experience in the fields of molecular genetics, microbiology, immunology, and pharmaceutical development. Most recently, Dr. Young was MedImmune’s president of research and development, where he had responsibility for regulatory affairs and was instrumental in the development of FluMist® and Synagis®. In 2005, Dr. Young was awarded the Albert B. Sabin Humanitarian Award. Prior to MedImmune, Dr. Young was influential in building the department of molecular genetics at Smith Kline & French Laboratories (now part of GlaxoSmithKline) and culminated as director, department of molecular genetics. Dr. Young was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York City, New York. He received his bachelor of science degrees in biology and general sciences from Villanova University and a doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas.

What is James F. Young's net worth?

The estimated net worth of James F. Young is at least $299,180.20 as of March 31st, 2022. Dr. Young owns 62,590 shares of Novavax stock worth more than $299,180 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Young may own. Learn More about James F. Young's net worth.

How do I contact James F. Young?

The corporate mailing address for Dr. Young and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on James F. Young's contact information.

Has James F. Young been buying or selling shares of Novavax?

James F. Young has not been actively trading shares of Novavax during the last quarter. Most recently, James F. Young sold 12,500 shares of the business's stock in a transaction on Thursday, March 31st. The shares were sold at an average price of $73.58, for a transaction totalling $919,750.00. Following the completion of the sale, the director now directly owns 62,590 shares of the company's stock, valued at $4,605,372.20. Learn More on James F. Young's trading history.

Who are Novavax's active insiders?

Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (EVP), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.

James F. Young Insider Trading History at Novavax

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2022Sell12,500$73.58$919,750.0062,590View SEC Filing Icon  
3/23/2021Sell10,000$228.22$2,282,200.0020,000View SEC Filing Icon  
6/3/2020Buy1,500$48.83$73,245.00View SEC Filing Icon  
8/31/2017Sell175,000$1.06$185,500.00View SEC Filing Icon  
6/18/2015Sell50,000$9.47$473,500.00View SEC Filing Icon  
6/6/2013Buy100,000$1.91$191,000.00View SEC Filing Icon  
3/11/2013Buy100,000$2.03$203,000.00View SEC Filing Icon  
See Full Table

James F. Young Buying and Selling Activity at Novavax

This chart shows James F Young's buying and selling at Novavax by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Novavax Company Overview

Novavax logo
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $4.78
Low: $4.76
High: $4.95

50 Day Range

MA: $4.59
Low: $3.76
High: $6.02

2 Week Range

Now: $4.78
Low: $3.53
High: $11.36

Volume

3,599,271 shs

Average Volume

8,629,882 shs

Market Capitalization

$668.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59